Skip to main content
. 2021 Oct 14;11:733848. doi: 10.3389/fonc.2021.733848

Table 1.

Clinical and pathological features of MCL cases analyzed.

Patient Age/sex Stage/MIPI IHC IgH/CCND1 FISH karyotype outcome
CD5 CD20 CD23 Ciclina D1 Ki-67%
MCL#1 68/M IVA + + + 10-15 nd nd A
MCL#2 66/F IVA + + + nd nd nd A
MCL#3 70/M IVB + + + nd nd nd normal D
MCL#4 76/F IVA/MIPI 5.9 (intermediate risk) + nd + nd + normal A
MCL#5 78/M IVA + + + 40 normal D
MCL#6 51/F IVB/MIPI 6.6 (high risk) nd + nd normal A
MCL#7 74/M IVA/MIPI 9 (high risk) + + + 40 + complex* A
MCL#8 81/F IVA + + + nd nd normal D
MCL#9 81/M IVA + ++ + nd nd D
MCL#10 65/M IVA/MIPI6.1 (intermediate risk) + + 10 normal A
MCL#11 55/F IVA + ++ + nd nd nd A
MCL#12 74/F IVA/MIPI 6.4 (high risk) + + + nd + Complex** A
MCL#13 72/F IVA/MIPI 6.1 (intermediate risk) + + + nd nd complex*** D
MCL#14 71/M nd + + + nd + complex**** D
MCL#15 85/F IVA + + + nd normal D
MCL#16 71/M IVA/MIPI 6.1 (intermediate risk) + + + nd + normal A
MCL#17 79/M IVA + ++ + + nd + complex° D
MCL#18 68/M IVB/MIPI high risk + ++ + nd + nd A
MCL#19 58/M IVA/MIPI 5.6 (intermediate risk) + + + nd + complex°° A
MCL#20 61/M IVA + + + nd + normal A

MIPI, Mantle cell International Prognostic Index; IHC, immunohistochemistry; nd, not determined; A, alive; D, death. M, male; F, female.

*43,XY,add(1)(q4)?,+3,del(6)(q13),-8,-9,der(10)t(10;13)(p13;q12),del(11)(q13),-13,-13,-14,+mar[13]/46,XY[12].ish add(1)(IGH++,CCND1++),der(11)t(11;14)(CCND1+,IGH+),add(?)(IGH+,CCND1+)[10].

**47XX,+3,del(6),t(10;15),t(11;14).

***62,XX,-X,-3,-5,+8,-12,-16,-17,dup(17)(p11p13),-18,+21,i(22)(q10),+mar[cp6]/46,XX[4].

****hyperdiploid karyotype due to a low number of mytosis with del(17)(p13) by FISH.

ᵒ42,X,-Y,+3,der(6;17)(q12;p11)?t(6;19)(q12;p13),i(8)(q10),der(11)t(11;14)(q13;q32),-13,-14,-15,add(15)(p13),add(20)(q13)[22]/46,XY[6].nuc ish(CCND1,IGH)x3(CCND1conIGHx2)[233/300].

ᵒᵒ43,C,-Y,+der(3)del(3)(p22)add(3)(q26),dic(4;6)(p16;q13),add(7)(p21),i(8)(q10),-10,t(11;14)(q13;q32),-13.der(15)t(10;15)(q21;q21),-20,-r[cp14]/46,XY[14].